Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Astellas Pharma and its US subsidiary Astellas Pharma US have entered into an agreement with Teva Pharmaceutical to settle the pending litigation with regard to US patent no 6,017,927 for Vesicare (solifenacin succinate) tablet through the entry of a consent judgment.
Subscribe to our email newsletter
Vesicare reduces muscle spasms of the bladder and urinary tract. Vesicare is used to treat symptoms of overactive bladder, such as frequent or urgent urination, and incontinence (urine leakage).
Vesicare is a muscarinic receptor antagonist. It works by blocking the action of certain chemicals in the body to help decrease urination problems caused by overactive bladder.
Astellas Pharma, Astellas and Teva said that, as a result of this settlement, the case is expected to be terminated by the consent judgment.
Additionally, settlement of the litigation provides Teva with the opportunity to launch a generic solifenacin succinate product in October, 2018, if Astellas does not obtain pediatric exclusivity.